JP2022505381A5 - - Google Patents

Info

Publication number
JP2022505381A5
JP2022505381A5 JP2021521383A JP2021521383A JP2022505381A5 JP 2022505381 A5 JP2022505381 A5 JP 2022505381A5 JP 2021521383 A JP2021521383 A JP 2021521383A JP 2021521383 A JP2021521383 A JP 2021521383A JP 2022505381 A5 JP2022505381 A5 JP 2022505381A5
Authority
JP
Japan
Prior art keywords
nucleic acid
acid construct
bidirectional nucleic
bidirectional
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021521383A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022505381A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/057092 external-priority patent/WO2020082047A1/en
Publication of JP2022505381A publication Critical patent/JP2022505381A/ja
Publication of JP2022505381A5 publication Critical patent/JP2022505381A5/ja
Pending legal-status Critical Current

Links

JP2021521383A 2018-10-18 2019-10-18 アルファ1アンチトリプシン欠乏症を治療するための組成物及び方法 Pending JP2022505381A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862747522P 2018-10-18 2018-10-18
US62/747,522 2018-10-18
PCT/US2019/057092 WO2020082047A1 (en) 2018-10-18 2019-10-18 Compositions and methods for treating alpha-1 antitrypsin deficiencey

Publications (2)

Publication Number Publication Date
JP2022505381A JP2022505381A (ja) 2022-01-14
JP2022505381A5 true JP2022505381A5 (cg-RX-API-DMAC7.html) 2022-10-27

Family

ID=68468858

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021521383A Pending JP2022505381A (ja) 2018-10-18 2019-10-18 アルファ1アンチトリプシン欠乏症を治療するための組成物及び方法

Country Status (16)

Country Link
US (2) US20200270618A1 (cg-RX-API-DMAC7.html)
EP (1) EP3867378A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022505381A (cg-RX-API-DMAC7.html)
KR (1) KR20210102209A (cg-RX-API-DMAC7.html)
CN (1) CN113195721A (cg-RX-API-DMAC7.html)
AU (1) AU2019361204A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021007289A2 (cg-RX-API-DMAC7.html)
CA (1) CA3116739A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021006367A2 (cg-RX-API-DMAC7.html)
EA (1) EA202191067A1 (cg-RX-API-DMAC7.html)
IL (1) IL282237A (cg-RX-API-DMAC7.html)
MX (1) MX2021004276A (cg-RX-API-DMAC7.html)
PH (1) PH12021550842A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202103735TA (cg-RX-API-DMAC7.html)
TW (1) TW202027797A (cg-RX-API-DMAC7.html)
WO (1) WO2020082047A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7383478B2 (ja) * 2016-12-22 2023-11-20 インテリア セラピューティクス,インコーポレイテッド アルファ1アンチトリプシン欠乏症を治療するための組成物および方法
IL326835A (en) 2018-10-16 2026-04-01 Blueallele Llc Methods for targeted insertion of dna genes
JP7578590B2 (ja) 2018-10-18 2024-11-06 インテリア セラピューティクス,インコーポレーテッド 第ix因子を発現するための組成物及び方法
CN113454105A (zh) 2019-02-08 2021-09-28 克里斯托生物技术股份有限公司 用于递送cftr多肽的组合物和方法
CN113939595A (zh) 2019-06-07 2022-01-14 瑞泽恩制药公司 包括人源化白蛋白基因座的非人动物
US12521451B2 (en) 2019-11-08 2026-01-13 Regeneron Pharmaceuticals, Inc. CRISPR and AAV strategies for x-linked juvenile retinoschisis therapy
CA3198727A1 (en) * 2020-10-20 2022-04-28 St Pharm Co., Ltd. Oligonucleotide for 5'-capped rna synthesis
US20220160847A1 (en) * 2020-11-20 2022-05-26 Mark Egly Method of preventing and/or treating a plurality of diseases
KR20240100492A (ko) * 2021-10-15 2024-07-01 인텔리아 테라퓨틱스, 인크. 알파-1 항트립신 결핍을 치료하기 위한 조성물 및 방법
MX2024004812A (es) * 2021-10-19 2024-07-15 Prec Biosciences Inc Métodos de edición génica para el tratamiento de la deficiencia de alfa-1 antitripsina (aat).
WO2024254519A2 (en) * 2023-06-08 2024-12-12 Mammoth Biosciences, Inc. Compositions and methods for the modification of human genes expressed by liver cells
WO2025128871A2 (en) 2023-12-13 2025-06-19 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5585481A (en) 1987-09-21 1996-12-17 Gen-Probe Incorporated Linking reagents for nucleotide probes
US5378825A (en) 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
ATE515510T1 (de) 1991-12-24 2011-07-15 Isis Pharmaceuticals Inc Durch dna-abschnitte unterbrochene modifizierte oligonukleotide
CA2186118C (en) 1994-03-23 2010-10-19 Richard W. Hanson Compacted nucleic acids and their delivery to cells
EP0760008A1 (en) 1994-05-19 1997-03-05 Dako A/S Pna probes for detection of neisseria gonorrhoeae and chlamydia trachomatis
CA2720903C (en) 2008-04-14 2019-01-15 Sangamo Biosciences, Inc. Linear donor constructs for targeted integration
JP5908725B2 (ja) 2008-08-22 2016-04-26 サンガモ バイオサイエンシーズ, インコーポレイテッド 標的一本鎖開裂および標的組込みのための方法、並びに組成物
US9255259B2 (en) 2010-02-09 2016-02-09 Sangamo Biosciences, Inc. Targeted genomic modification with partially single-stranded donor molecules
ES2728782T3 (es) 2012-05-25 2019-10-28 Univ California Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
EP4397759A3 (en) 2012-10-23 2024-10-09 Toolgen Incorporated Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof
WO2014093694A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
ES2887254T3 (es) 2013-03-08 2021-12-22 Novartis Ag Lípidos y composiciones lipídicas para el suministro de agentes activos
EP2997146A4 (en) * 2013-05-15 2017-04-26 Sangamo BioSciences, Inc. Methods and compositions for treatment of a genetic condition
US10059655B2 (en) 2013-12-19 2018-08-28 Novartis Ag Lipids and lipid compositions for the delivery of active agents
WO2015200555A2 (en) 2014-06-25 2015-12-30 Caribou Biosciences, Inc. Rna modification to engineer cas9 activity
CN106794141B (zh) 2014-07-16 2021-05-28 诺华股份有限公司 将核酸包封在脂质纳米粒主体中的方法
CN113337533A (zh) 2014-12-23 2021-09-03 先正达参股股份有限公司 用于鉴定和富集包含位点特异性基因组修饰的细胞的方法和组合物
AU2016226077B2 (en) 2015-03-03 2021-12-23 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases with altered PAM specificity
US11279928B2 (en) 2015-06-29 2022-03-22 Massachusetts Institute Of Technology Compositions comprising nucleic acids and methods of using the same
WO2017093804A2 (en) * 2015-12-01 2017-06-08 Crispr Therapeutics Ag Materials and methods for treatment of alpha-1 antitrypsin deficiency
WO2017136794A1 (en) 2016-02-03 2017-08-10 Massachusetts Institute Of Technology Structure-guided chemical modification of guide rna and its applications
EP3433364A1 (en) * 2016-03-25 2019-01-30 Editas Medicine, Inc. Systems and methods for treating alpha 1-antitrypsin (a1at) deficiency
ES3030658T3 (en) 2016-03-30 2025-07-01 Intellia Therapeutics Inc Lipid nanoparticle formulations for crispr/cas components
EP3551757A1 (en) 2016-12-08 2019-10-16 Intellia Therapeutics, Inc. Modified guide rnas
JP7383478B2 (ja) 2016-12-22 2023-11-20 インテリア セラピューティクス,インコーポレイテッド アルファ1アンチトリプシン欠乏症を治療するための組成物および方法
IL311278B2 (en) 2017-09-29 2026-05-01 Intellia Therapeutics Inc Polynucleotides, compositions, and methods for genome editing
IL326835A (en) 2018-10-16 2026-04-01 Blueallele Llc Methods for targeted insertion of dna genes

Similar Documents

Publication Publication Date Title
JP7832262B2 (ja) 肝特異的ウイルスプロモーター及びその使用方法
JP2023523237A (ja) snRNA構成要素を使用する組成物及び方法
EP2940131B1 (en) Aav variant
JP6495273B2 (ja) 変異aav、及び、細胞、臓器並びに組織への遺伝子導入のための組成物、方法並びに使用法
JP2022513456A5 (cg-RX-API-DMAC7.html)
JP2022534809A5 (cg-RX-API-DMAC7.html)
JP2022512726A5 (cg-RX-API-DMAC7.html)
CN114450031A (zh) 靶向rna的敲低和替代组合物及使用方法
JP6824169B2 (ja) 改変g6pcをコードするアデノ随伴ウイルスベクターおよびその使用
JP2016517278A (ja) スタッファー/フィラーポリヌクレオチド配列を含むベクターおよびその使用方法
JP2022553573A5 (cg-RX-API-DMAC7.html)
CN119137273A (zh) 包括工程化核内小RNA(snRNA)的组合物和方法
WO2019152816A1 (en) Campaign-ready series of recombinant adeno-associated virus (raav) complementing plasmids
WO2020142714A1 (en) Aav expression cassette and aav vectors comprising the same
US20240398990A1 (en) Liver-specific expression cassettes, vectors and uses thereof for expressing therapeutic proteins
CN119403823A (zh) 具有增强的肌肉转导效率的肽修饰的aav衣壳
JP2024546196A (ja) USH2A pre-mRNAを標的とするsnRNA、及びその使用
CN120129747A (zh) snRNA核酸分子及其应用
EP4100523A2 (en) Compositions and methods for circular rna expression
TWI903434B (zh) 具有改良負載基因表現率及降低基因毒性之腺相關病毒之經修飾複合體平台
US11993783B1 (en) Nucleic acid molecule comprising asymmetrically modified ITR for improving expression rate of inserted gene, and use thereof
CN112041437A (zh) 用于恢复f8基因功能的腺相关病毒组合物和其使用方法
JP2025500685A (ja) ヌクレオチド及びその使用
CN105358690B (zh) 启动子组合物
JP2022523320A5 (cg-RX-API-DMAC7.html)